Transcribe to survive: Transcriptional control of antioxidant defense programs for neuroprotection in parkinson's disease

Antioxidants and Redox Signaling

Volumn 11, Issue 3, 2009, Pages 509-528

  Clark, Joanne ^a   Simon, David K ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLYCOGEN SYNTHASE KINASE 3BETA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; NEUROPROTECTIVE AGENT;

AGING; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE THERAPY; GENETIC TRANSCRIPTION; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION; HUMAN; METABOLISM;

ANTIOXIDANTS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TRANSCRIPTION, GENETIC;

MUS;

EID: 58849090439     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2008.2241     Document Type: Review

References (226)

1. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, and Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69: 1326-1329. 1997.
2. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, and Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196-1203, 1997.
3. An JH, Vranas K, Lucke M, Inoue H, Hisamoto N, Matsumoto K, and Blackwell TK. Regulation of the Caenorhabditis elegans oxidative stress defense protein SKN-1 by glycogen synthase kinase-3. Proc Natl Acad Sci USA 102: 16275-16280, 2005.
4. Anderson RM, Barger JL, Edwards MG, Braun KH, O'Connor CE, Prolla TA, and Weindruch R. Dynamic regulation of PGC-1alpha localization and turnover implicates mitochondrial adaptation in calorie restriction and the stress response. Aging Cell 7: 101-111, 2008.
5. Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM, Thomas B, Ko HS, Sasaki M, Ischiropoulos H, Przedborski S, Dawson TM, and Dawson VL. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci 104: 14807-14812, 2007.
6. Apopa PL, He X, and Ma Q. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J Biochem Mol Toxicol 22: 63-76, 2008
7. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357-66, 1995.
8. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann NY Acad Sci 991: 120-131, 2003.
9. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, and Turnbull DM. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38: 515-517, 2006.
10. Betarbet R, Sherer TB, Di Monte DA, and Greenamyre JT. Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol 12: 499-510, 2002.
11. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, and Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306, 2000.
12. Bian Z, Elner SG, Yoshida A, and Elner VM. Differential involvement of phosphoinositide 3-kinase/Akt in human RPE MCP-1 and IL-8 expression. Invest Ophthalmol Vis Sci 45: 1887-1896, 2004.
13. Blank V. Small Maf proteins in mammalian gene control: Mere dimerization partners or dynamic transcriptional regulators? J Mol Biol 376: 913-925, 2008.
14. Bloom DA and Jaiswal AK. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem 278: 44675-44682, 2003.
15. Bohmann D, Bos TJ, Admon A, Nishimura T, Vogt PK, and Tjian R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238: 1386-1392, 1987.
16. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, Brice A, van Duijn CM, Oostra B, Meco G, and Heutink P. DJ-1 ( PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24: 159-160, 2003.
17. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259 2003.
18. Bowling AC and Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 56: 1151-1171, 1995.
19. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, and Hirsch EC. rotective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82: 615-624, 2002.
20. Burton NC, Kensler TW, and Guilarte TR. In vivo modulation of the Parkinsonian phenotype by Nrf2. NeuroToxicology 27: 1094-1100., 2006
21. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, and Johnson JA. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci USA 102: 244-249, 2005.
22. Cantuti-Castelvetri I, Lin MT, Zheng K, Keller-McGandy CE, Betensky RA, Johns DR, Beal MF, Standaert DG, and Simon DK. Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol Aging 26: 1343-1355, 2005.
23. Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JP, Parker WD Jr., and Bennett JP Jr. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1362: 77-86, 1997.
24. Chan JY, Cheung MC, Moi P, Chan K, and Kan YW. Chromosomal localization of the human NF-E2 family of bZIP transcription factors by fluorescence in situ hybridization. Hum Genet 95: 265-269, 1995.
25. Chen G, Bower KA, Ma C, Fang S, Thiele CJ, and Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 18: 1162-1164, 2004.
26. Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, and Andersen JK. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neurosci 27: 13997-14006, 2007.
27. Conway KA, Rochet JC, Bieganski RM, and Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294: 1346-1349, 2001.
28. Cullinan SB and Diehl JA. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol 38: 317-332, 2006.
29. Cullinan SB, Gordan JD, Jin J, Harper JW, and Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 24: 8477-8486, 2004.
30. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, and Diehl JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23: 7198-7209, 2003.
31. Czubryt MP, McAnally J, Fishman GI, and Olson EN. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci USA 100: 1711-1716, 2003.
32. Dalle-Donne I, Rossi R, Giustarini D, Colombo R, and Milzani A. S-glutathionylation in protein redox regulation. Free Radic Biol Med 43: 883-898, 2007.
33. Damier P, Hirsch EC, Zhang P, Agid Y, and Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52: 1-6, 1993.
34. Dehmer T, Heneka MT, Sastre M, Dichgans J, and Schulz JRB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation. J Neurochem 88: 494-501, 2004.
35. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, and Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389, 989.
36. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells R, Daniel SE, Lees AJ, Jenner P, and Marsden CD. 1994. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9: 92-97, 1994.
37. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR , Daniel SE, Lees AJ, Schapira AH, and et al. 1994. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35: 38-44, 1994.
38. Di Monte DA, Chan P, and Sandy MS. 1992. Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage? Ann Neurol 32: S111-115, 1992.
39. Diaz VM, Mori S, Longobardi E, Menendez G, Ferrai C, Keough RA, Bachi A, and Blasi F. p160 Myb-binding protein interacts with Prep1 and inhibits its transcriptional activity. Mol Cell Biol 27: 7981-7990, 2007.
40. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, and Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci 99: 11908-11913, 2002.
41. Dinkova-Kostova AT, Holtzclaw WD, and Wakabayashi N. Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein. Biochemistry 44: 6889-6899, 2005.
42. Duarte AI, Santos P, Oliveira CR, Santos MS, and Rego AC. Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression. Biochim Biophys Acta 1783: 994-1002, 2008.
43. Duda JE, Giasson BI, Chen Q, Gur TL, HHurtig HI, Stern MB, Gollomp SM, Ischiropoulos H, Lee VM, and Trojanowski JQ. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 157: 1439-1445, 2000.
44. Esterbauer H, Oberkofler H, Krempler F, and Patsch W. Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics 62: 98-102, 1999.
45. Fan M, Rhee J, St-Pierre J, Handschin C, Puigserver P, Lin J, Jaeger S, Erdjument-Bromage H, Tempst P, and Spiegelman BM. Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev 18: 278-289, 2004.
46. Favreau LV and Pickett CB. The rat quinone reductase antioxidant response element. Identification of the nucleotide sequence required for basal and inducible activity and detection of antioxidant response element-binding proteins in hepatoma and non-hepatoma cell lines. J Biol Chem 270: 24468-24474, 1995.
47. Furukawa M and Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 25: 162-171, 2005.
48. Galloway DC, Blake DG, and McLellan LI. Regulation of gamma-glutamylcysteine synthetase regulatory subunit (GLCLR) gene expression: identification of the major transcriptional start site in HT29 cells. Biochim Biophys Acta 1446: 47-56, 1999.
49. Galloway DC, Blake DG, Shepherd AG, and McLellan LI. Regulation of human gamma-glutamylcysteine synthetase: co-ordinate induction of the catalytic and regulatory subunits in HepG2 cells. Biochem J 328: 99-104, 1997.
50. Gassen M, Pinchasi B, and Youdim MB. Apomorphine is a potent radical scavenger and protects cultured pheochromocytoma cells from 6-OHDA and H2O2-induced cell death. Adv Pharmacol 42: 320-324, 1998.
51. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, and Lee VM. Oxidative damage linked to neurodegeneration by selective alpha- synuclein nitration in synucleinopathy lesions. Science 290:985-989, 2000.
52. Good PF, Hsu A, Werner P, DPerl DP, and Olanow CW. 1998. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57:338-342 1998.
53. Graveley BR. Sorting out the complexity of SR protein functions. RNA 6:1197-1211, 2000.
54. Gregory MA, Qi Y, and Hann SR. Phosphorylation by glycogen sunthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 278: 51606-51612, 2003.
55. Gu M, Cooper JM, Taanman JW, and Schapira AH. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 44: 177-186, 1998.
56. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, and Shults CW. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37: 714-722, 1995.
57. Handschin C, Rhee J, Lin J, Tarr PT, and Spiegelman BM. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc Natl Acad Sci USA 100: 7111-7116, 2003.
58. Handschin C and Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27: 728-735 2006.
59. Hara H, Ohta M, and Adachi T. Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J Neurosci Res 84: 860-866, 2006.
60. Hara H, Ohta M, Ohta K, Kuno S, and Adachi T. Apomorphine attenuates 6-hydroxydopamine-induced apoptotic cell death in SH-SY5Y cells. Redox Rep 8: 193-197, 2004.
61. Hasegawa E, Takeshige K, Oishi T, Murai Y, and Minakami S. 1-methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 170:1049-1055, 1990.
62. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, and Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha- synuclein in vitro. Neuroreport 10: 717-721, 1999.
63. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Puigserver P, Spiegelman B, and Montminy M. 2CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413: 179-183, 2001.
64. Hetman M and Kharebava G. Survival signaling pathways activated by NMDA receptors. Curr Top Med Chem 6: 787-799, 2006.
65. Hintze KJ, Keck AS, Finley JW, and Jeffery EH. Induction of hepatic thioredoxin reductase activity by sulforaphane, both in Hepa1c1c7 cells and in male Fisher 344 rats. J Nutr Biochem 14: 173-179, 2003.
66. Huang HM, Huang CJ, and Yen JJ. Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways. Blood 96: 1764-1771, 2000.
67. Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, and Stern GM. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 8: 165-170, 1993.
68. Hulleman JD, Mirzaei H, Guigard E, Taylor KL, Ray SS, Kay CM, Regnier FE, and Rochet JC. Destabilization of DJ-1 by familial substitution and oxidative modifications: implications for Parkinson's disease. Biochemistry 46: 5776-57789, 2007.
69. Hurttila H, Koponen JK, Kansanen E, Jyrkkanen HK, Kivela A, Kylatie R, Yla-Herttuala S, and Levonen AL. Oxidative stress-inducible lentiviral vectors for gene therapy. Gene Ther 15: 1271-1279, 2008.
70. Ishii T, Itoh K, Sato H, and Bannai S. Oxidative stress-inducible proteins in macrophages. Free Radic Res 31: 351-355, 1999.
71. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, SatohK, Hatayama I, Yamamoto M, and Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322, 1997.
72. Itoh K, Ishii T, Wakabayashi N, and Yamamoto M. Regulatory mechanisms of cellular response to oxidative stress. Free Radic Res 31: 319-324, 1999.
73. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86, 1999.
74. Jain AK and Jaiswal AK. Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J Biol Chem 281: 12132-112142, 2006.
75. Jain AK, Mahajan S, and Jaiswal AK. Phosphorylation and dephosphorylation of tyrosine 141 regulates stability and degradation of INrf2: A novel mechanism in Nrf2 activation. J Biol Chem 283: 17712-17720, 2008.
76. Jakel RJ, Townsend JA, Kraft AD, and Johnson JA. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res1144: 192-201, 2007.
77. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 146:6-13, 1993.
78. Jenner P. 2003. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3: S26-36; discussion S36-38, 2003.
79. Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu RM, Forman HJ, and Andersen JK. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J Biol Chem 275: 26096-26101, 2000.
80. Jia Z, Zhu H, Misra BR, Li Y, and Misra HP. Dopamine as a potent inducer of cellular glutathione and NAD(P)H:quinone oxidoreductase 1 in PC12 neuronal cells: A potential adaptive mechanism for dopaminergic neuroprotection. Neurochem Res 33: 2197-2205, 2008.
81. Jia Z, Zhu H, Misra HP, and Li Y. Potent induction of total cellular GSH and NQO1 as well as mitochondrial GSH by 3H-1,2-dithiole-3-thione in SH-SY5Y neuroblastoma cells and primary human neurons: protection against neurocytotoxicity elicited by dopamine, 6-hydroxydopamine, 4-hydroxy-2-nonenal, or hydrogen peroxide. Brain Res 1197: 159-169, 2008.
82. Johnson DA, Andrews GK, Xu W, and Johnson JA. Activation of the antioxidant response element in primary cortical neuronal cultures derived from transgenic reporter mice. J Neurochem 81: 1233-1241, 2002.
83. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, Lee HC, and Cha BS. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem Biophys Res Commun 340: 221-227, 2006.
84. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, Lee HC, and Cha BS. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci 253: 53-60, 2007.
85. Kang KW, Lee SJ, Park JW, and Kim SG. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol Pharmacol 62: 1001-1010, 2002.
86. Kang MI, Kobayashi A, Wakabayashi N, Kim SG, and Yamamoto M. 2004. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc Natl Acad Sci USA 101: 2046-2051.
87. Kataoka K, Nishizawa M, and Kawai S. Structure-function analysis of the maf oncogene product, a member of the b-Zip protein family. J Virol 67: 2133-2141, 1993.
88. Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, and Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 6: 857-868, 2001.
89. Kern JT, Hannink M, and Hess JF. Disruption of the Keap1-containing ubiquitination complex as an antioxidant therapy. Curr Top Med Chem 7: 972-978, 2007.
90. Keum Y-S, Yu S, Chang PPJ, Yuan X, Kim JH, Xu C, Han J, Agarwal A, and T. Kong AN. Mechanism of action of sulforaphane: Inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res 66: 8804-8813, 2006.
91. Kim TK, Kim TH, and Maniatis T. Efficient recruitment of TFIIB and CBP-RNA polymerase II holoenzyme by an interferon-beta enhanceosome in vitro. Proc Natl Acad Sci USA 95: 12191-12196, 1998.
92. Kitani K, Miyasaka K, Kanai S, Carrillo MC, and Ivy GO. Upregulation of antioxidant enzyme activities by deprenyl. Implications for life span extension. Ann NY Acad Sci 786: 391-409, 1996.
93. Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, and Beal MF. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine. J Neurosci 20: 1-7, 2000.
94. Knutti D, Kaul A, and Kralli A. A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol Cell Biol 20: 2411-2422, 2000.
95. Knutti D and Kralli A. PGC-1, a versatile coactivator. Trends Endocrinol Metab 12: 360-365, 2001.
96. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, and Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24: 7130-7139, 2004.
97. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, and Yamamoto M. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol 26: 221-229, 2006.
98. Kobayashi M, Itoh K, Suzuki T, Osanai H, Nishikawa K, Katoh Y, Takagi Y, and Yamamoto M. Identification of the interactive interface and phylogenic conservation of the Nrf2-Keap1 system. Genes Cells 7: 807-820, 2002.
99. Kops GJPL, Dansen TB, Polderman PE, Saarloos I, Wirtz KWA, Coffer PJ, Huang TT, Bos JL, Medema RH, and Burgering BMT. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419: 316-321, 2002.
100. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, and Ferrante RJ. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11: 211-213, 2000.
101. Kozikowski AP, Gaisina IN, Petukhov PA, Sridhar S, King LT, Blond SY, Duka T, Rusnak M, and Sidhu A. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. Chem Med Chem 1: 256-266, 2006.
102. Kraft AD, Johnson DA, and Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24: 1101-1112, 2004.
103. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, and Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 38: 518-520, 2006.
104. Krige D, Carroll MT, Cooper JM, Marsden CD, and Schapira AH. 1992. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 32: 782-788, 1992.
105. Kushnareva Y, Murphy AN, and Andreyev A. 2002. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem J 368: 545-553, 2002.
106. Langston JW. 1996. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47: S153-160, 1996.
107. Lau KF, Miller CCJ, Anderton BH, and Shaw PC. Expression analysis of glycogen synthase kinase-3 in human tissues. J Peptide Res 54: 85-91, 1999.
108. Lee BS, Heo J, Kim YM, Shim SM, Pae HO, Kim YM, and Chung HT. Carbon monoxide mediates heme oxygenase 1 induction via Nrf2 activation in hepatoma cells. Biochem Biophys Res Commun 343: 965-972, 2006.
109. Lee JM, Calkins MJ, Chan K, Kan YW, and Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 278: 12029-12038, 2003.
110. Lee JM, Hanson JM, Chu WA, and Johnson JA. Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J Biol Chem 276: 20011-20016, 2001.
111. Lees AJ. Dopamine agonists in Parkinson's disease: A look at apomorphine. Fundam Clin Pharmacol 7: 121-128, 1993.
112. Lerin C, Rodgers JT, Kalume DE, Kim SH, Pandey A, and Puigserver P. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1[alpha]. Cell Metab 3: 429-438, 2006.
113. Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, and Heidenreich KA. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol Cell Biol 20: 9356-9363, 2000.
114. Lim JH, Kim KM, Kim SW, Hwang O, and Choi HJ. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: Novel cytoprotective mechanism against oxidative damage. Pharmacol Res 57: 325-331, 2008.
115. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription co-activators. Cell Metab 1: 361-370, 2005.
116. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, Mootha VK, Jager S, Vianna CR, Reznick RM, Cui L, Manieri M, Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM, Cinti S, Shulman GI, Lowell BB, Krainc D, and Spiegelman BM. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119: 121-135, 2004.
117. Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA, Bouchard RJ, Florez-McClure ML, and Heidenreich KA. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 24: 9993-10002, 2004.
118. Liu F, Nguyen JL, Hulleman JD, Li L, and Rochet J-C. Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. J Neurochem 105: 2435-2453, 2008.
119. Lockhart PJ, Lincoln S, Hulihan M, Kachergus J, Wilkes K, Bisceglio G, Mash DC, and Farrer MJ. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet 41: e22-, 2004.
120. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, and Marsden CD. 1992. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115: 333-342, 1992.
121. Martinat C, Shendelman S, Jonason A, Leete T, Beal MF, Yang L, Floss T, and Abeliovich A. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary parkinsonism. PLoS Biol 2: e327, 2004.
122. McCubrey JA, LaHair MM, and Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 8: 1775-1789, 2006.
123. McEwan IJ. Gene regulation through chromatin remodelling by members of the nuclear receptor superfamily. Biochem Soc Trans 28: 369-373, 2000.
124. McMahon M, Thomas N, Itoh K, Yamamoto M, and Hayes JD. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem 279: 31556-31567, 2004.
125. Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, and Beal MF. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 34: 609-616, 1993.
126. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, and Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163: 1450-1455, 1989.
127. Monsalve M, Wu Z, Adelmant G, Puigserver P, Fan M, and Spiegelman BM. Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Mol Cell 6: 307-316, 2000.
128. Montminy MR and Bilezikjian LM. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 328: 175-178, 1987.
129. Moore DJ, Masliah E, Rippeth JD, Gonzalez R, Carey CL, Cherner M, Ellis RJ, Achim CL, Marcotte TD, Heaton RK, and Grant I. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. Aids 20: 879-887, 2006.
130. Mulcahy RT and Gipp JJ. Identification of a putative antioxidant response element in the 5′-flanking region of the human gamma-glutamylcysteine synthetase heavy subunit gene. Biochem Biophys Res Commun 209: 227-233, 1995.
131. Nakaso K, Nakamura C, Sato H, Imamura K, Takeshima T, and Nakashima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem Biophys Res Commun 339: 915-922, 2006.
132. Neish AS, Anderson SF, Schlegel BP, Wei W, and Parvin JD. Factors associated with the mammalian RNA polymerase II holoenzyme. Nucleic Acids Res 26: 847-8-53, 1998.
133. Nemoto S and Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295: 2450-2452, 2002.
134. Nioi P, Nguyen T , Sherratt PJ, and Pickett CB. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol Cell Biol 25: 10895-10906, 2005.
135. O'Neill JP, Rogan PK, Cariello N, and Nicklas JA. Mutations that alter RNA splicing of the human HPRT gene: A review of the spectrum. Mutat Res 411: 179-214, 1998.
136. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M, and Hirohashi S. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68: 1303-1309, 2008.
137. Olson BL, Hock MB, Ekholm-Reed S, Wohlschlegel JA, Dev KK, A Kralli and Reed SI. SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis. Genes Dev 22: 252-264, 2008.
138. Owen HR, Elser M, Cheung E, Gersbach M, Kraus WL, and Hottiger MO. MYBBP1a is a novel repressor of NF-[kappa]B. J Mol Biol 366: 725-736, 2007.
139. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S, and Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21: 689-700, 2006.
140. Parker WD Jr, Boyson SJ, and Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-723, 1989.
141. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VM, and Ischiropoulos H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 21: 8053-8061, 2001.
142. Pearson KJ, Lewis KN, Price NL, Chang JW, Perez E, Cascajo MV, Tamashiro KL, Poosala S, Csiszar A, Ungvari Z, Kensler TW, Yamamoto M, Egan JM, Longo DL, Ingram DK, Navas P, and de Cabo R. Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. Proc Natl Acad Sci USA 105: 2325-2330, 2008.
143. Perry TL, Godin DV, and Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305-310, 1982.
144. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 22(Suppl 1): S20-S27, 2007.
145. Pitkanen S and Robinson BH. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest 98: 345-351, 1996.
146. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, and Woodgett JR. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1114: 147-162 1992.
147. Poirier J and Barbeau A. A catalyst function for MPTP in superoxide formation. Biochem Biophys Res Commun 131: 1284-1289, 1985.
148. Prestera T, Talalay P, Alam J, Ahn YI, Lee PJ, and Choi AM. Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol Med 1: 827-837, 1995.
149. Puigserver P, Adelmant G, Wu Z, Fan M, Xu J, O'Malley B, and Spiegelman BM. Activation of PPARgamma coactivator-1 through transcription factor docking. Science 286: 1368-1371, 1999.
150. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D, and Spiegelman BM. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423: 550-555, 2003.
151. Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB, and Spiegelman BM. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 8: 971-982, 2001.
152. Puigserver P and Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 24: 78-90, 2003.
153. Quesada A, Lee BY, and Micevych PE. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev Neurobiol 68: 632-644, 2008.
154. Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, Medhurst AD, and Virley DJ. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
155. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, and Kensler TW.. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98: 3410-3415, 2001.
156. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, and Jordan-Sciutto KL. Expression of Nrf2 in Neurodegenerative Diseases. J Neuropathol Exp Neurol 66: 75-85, 2007.
157. Reliene R and Schiestl RH. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis 27: 240-244, 2006.
158. Rojo AI, Sagarra MR, and Cuadrado A. GSK-3beta downregulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 105: 192-202, 2008.
159. Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee meeting. N Engl J Med 357: 844-846, 2007.
160. Rushmore TH, Morton MR, and Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 266: 11632-11639, 1991.
161. Rushmore TH and Pickett CB. Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. J Biol Chem 265: 14648-14653, 1990.
162. Sadowski M, Mawson A, Baker R, and Sarcevic B. Cdc34 C-terminal tail phosphorylation regulates Skp1/cullin/F-box (SCF)-mediated ubiquitination and cell cycle progression. Biochem J 405: 569-581, 2007.
163. Salazar M, Rojo AI, Velasco D, de Sagarra RM, and Cuadrado A. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem 281: 14841-14851, 2006.
164. Sanchez-Ramos RR, Overvik E, and Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigra-striatum of Parkinson's disease. Neurodegeneration 3: 197-204, 1994.
165. Sano M, Tokudome S, Shimizu N, Yoshikawa N, Ogawa C, Shirakawa K, Endo J, Katayama T, Yuasa S, Ieda M, Makino S, Hattori F, Tanaka H, and Fukuda K. Intramolecular control of protein stability, subnuclear compartmentalization, and coactivator function of peroxisome proliferator-activated receptor {gamma} coactivator 1{alpha}. J Biol Chem 282: 25970-25980, 2007.
166. Schäfer M, Goodenough S, Moosmann B, and Behl C. Inhibition of glycogen synthase kinase 3[beta] is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res 1005: 84-89, 2004.
167. Schapira AH. Neurotoxicity and the mechanisms of cell death in Parkinson's disease. Adv Neurol 69: 161-165, 1996.
168. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, and Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease [letter] [see comments]. Lancet 1: 1269, 1989
169. Schulz JB and Beal MF. Mitochondrial dysfunction in movement disorders. Curr Opinion Neurol 7: 333-339, 1994.
170. Schulz JB, Lindenau J, Seyfried J, and Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 267: 4904-4911, 2000.
171. Sherer TB, Betarbet R, and Greenamyre JT.. Environment, mitochondria, and Parkinson's disease. Neuroscientist 8: 192-197, 2002.
172. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, and Greenamyre JT. An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22: 7006-7015, 2002.
173. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, and Greenamyre JT. Mechanisms of toxicity in rotenone models of Parkinson's disease. J Neurosci 23: 10756-10764, 2003.
174. Shih AY, Erb H, and Murphy TH. Dopamine activates Nrf2-regulated neuroprotective pathways in astrocytes and meningeal cells. J Neurochem 101: 109-119, 2007.
175. Shimura-Miura H, Hattori N, Kang D, Miyako K, Nakabeppu Y, and Mizuno Y. 1999. Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Ann Neurol 46: 920-924, 1999.
176. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, and Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420, 2006.
177. Sinha BK, Singh Y, and Krishna G.. Formation of superoxide and hydroxyl radicals from 1-methyl-4-phenylpyridinium ion (MPP+): Reductive activation by NADPH cytochrome P-450 reductase. Biochem Biophys Res Commun 135: 583-588, 1986.
178. Skowyra D, Craig KL, Tyers M, Elledge SJ, and Harper JW. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91: 209-219, 1997.
179. Smith PD, Mount MP, Shree R, Callaghan S, Slack RS, Anisman H, Vincent I, Wang X, Mao Z, and Park DS. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 26: 440-447, 2006.
180. Sofic E, Lange KW, Jellinger K, and Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142: 128-130, 1992.
181. Souza JM, Giasson BI, Chen Q, Lee VM, and Schiropoulos H. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275: 18344-18349, 2000.
182. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, and Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397-408, 2006.
183. Stambolic V and Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 303: 701-704, 1994.
184. Sudarsanam P and Winston F. The Swi/Snf family: nucleosome-remodeling complexes and transcriptional control. Trends Genet 16: 345, 2000.
185. Sun Z, Zhang S, Chan JY, and Zhang DD. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol Cell Biol 27: 6334-6349, 2007.
186. Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuck V, Jin J, Harper JW, and Ericsson J. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbx7). Cell Metab 1: 379-391, 2005.
187. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP Jr, Davis RE, and Parker WD Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40: 663-671, 1996.
188. Takagi Y, Kobayashi M, Li L, Suzuki T, Nishikawa K , and Yamamoto M. MafT, a new member of the small Maf protein family in zebrafish. Biochem Biophys Res Commun 320: 62-69, 2004.
189. Tatton WG, Chalmers-Redman R, Brown D, and Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 53 Suppl 3: S61-70; discussion S70-72, 2003.
190. Theodore M, Kawai Y, Yang J, Kleshchenko Y, Reddy SP, Villalta F, and Arinze IJ. Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2. J Biol Chem 283: 8984-8994, 2008.
191. Thomas B and Beal MF. Parkinson's disease. Hum Mol Genet 16: R183-194, 2007.
192. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL, Sabio G, Davis RJ, Matthews DE, Doble B, and Rincon M. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 320: 667-670, 2008.
193. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, and Yamamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol 26: 2887-2900, 2006.
194. Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, Yokoyama S, and Yamamoto M. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 27: 7511-7521, 2007.
195. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly YM, Gidlof S, Oldfors A, Wibom R, Tornell J, Jacobs HT, and Larsson NG. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429: 417-423, 2004.
196. Tritos NA, Mastaitis JW, Kokkotou EG, Puigserver P, Spiegelman BM, and Maratos-Flier E. Characterization of the peroxisome proliferator activated receptor coactivator 1 alpha (PGC 1alpha) expression in the murine brain. Brain Res 961: 255-260, 2003.
197. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, and Monsalve M. PGC-1{alpha} regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res 66: 562-573, 2005.
198. van Muiswinkel FL, de Vos RAI, Bol JGJM, Andringa G, Jansen Steur ENH, Ross D, Siegel D, and Drukarch B. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 25: 1253-1262, 2004.
199. Velichkova M, Guttman J, Warren C, Eng L, Kline K, Vogl AW, and Hasson T. A human homologue of Drosophila kelch associates with myosin-VIIa in specialized adhesion junctions. Cell Motil Cytoskel 51: 147-164, 2002.
200. Velichkova M and Hasson T. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol Cell Biol 25: 4501-4513, 2005.
201. Vermulst M, Bielas JH, Kujoth GC, Ladiges WC, Rabinovitch PS, Prolla TA, and Loeb LA. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet 39: 540-543, 2007.
202. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, and Przedborski S. alpha-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 74: 721-729, 2000.
203. Vo N and Goodman RH. CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 276: 13505-13508, 2001.
204. Wallberg AE, Yamamura S, Malik S, Spiegelman BM, and Roeder RG. Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1alpha. Mol Cell 12: 1137-1149, 2003.
205. Wang B and Williamson G. Detection of a nuclear protein which binds specifically to the antioxidant responsive element (ARE) of the human NAD(P) H:quinone oxidoreductase gene. Biochim Biophys Acta 1219: 645-652, 1994.
206. Wang L, Liu J, Saha P, Huang J, Chan L, Spiegelman B, and Moore DD. The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes. Cell Metab 2: 227-238, 2005.
207. Wang W, Yang Y, Ying C, Li W, Ruan H, Zhu X, You Y, Han Y, Chen R, Wang Y, and Li M. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 52: 1678-1684, 2007.
208. Wang X-J, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, and Zhang DD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29: 1235-1243, 2008.
209. Wei W, Jin J, Schlisio S, Harper JW, and Kaelin WG. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8: 25-33, 2005.
210. Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M, Clurman BE, and Roberts JM. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 12: 381-392, 2003.
211. Wruck CJ, Claussen M, Furhrmann G, Romer L, Schult A, Pufe T, Waetzig V, Peipp M, Herdegen T, and Gotz ME. Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J Neural Transm Suppl 72: 57-67, 2007.
212. Wu CC, Hsieh CW, Lai PH, Lin JB, Liu YC, and Wung BS. Upregulation of endothelial heme oxygenase-1 expression through the activation of the JNK pathway by sublethal concentrations of acrolein. Toxicol Appl Pharmacol 214: 244-252, 2006.
213. Wu Z, Puigserver P, and Spiegelman BM. Transcriptional activation of adipogenesis. Curr Opin Cell Biol 11: 689-694, 1999.
214. Wullner U, Loschmann PA, Schulz JB, Schmid A, Dringen R, Eblen F, Turski L, and Klockgether T. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. Neuroreport 7: 921-923, 1996.
215. Xu J, Kao SY, Lee FJ, Song W, Jin LW, and Yankner BA. Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8: 600-606, 2002.
216. Yamamoto T, Kyo M, Kamiya T, Tanaka T, Engel JD, Motohashi H, and Yamamoto M. Predictive base substitution rules that determine the binding and transcriptional specificity of Maf recognition elements. Genes Cells 11: 575-591, 2006.
217. Yamauchi T, RKeough RA, Gonda TJ, and Ishii S. Ribosomal stress induces processing of Mybbp1a and its translocation from the nucleolus to the nucleoplasm. Genes Cells 13: 27-39, 2008.
218. Yang P, Peairs YJ, Tano R, and Jaffe GJ. Oxidant-mediated Akt activation in human RPE cells. Invest Ophthalmol Vis Sci 47: 4598-4606, 2006.
219. Yang Y, Gehrke S, Haque ME, Imai Y, Kosek J, Yang L, Beal MF, Nishimura I, Wakamatsu K, Ito S, Takahashi R, and Lu B. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 102: 13670-13675, 2005.
220. Yu CF and Basson MD. 2000. Matrix-specific FAK and MAPK reorganization during Caco-2 cell motility. Microsc Res Tech 51: 191-203, 2000.
221. Zang LY and Misra HP. Superoxide radical production during the autoxidation of 1-methyl-4- phenyl-2,3-dihydropyridinium perchlorate. J Biol Chem 267: 17547-17552, 1992.
222. Zhang DD, Lo SC, Cross JV, Templeton DJ, and Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24: 10941-10953, 2004.
223. Zhang J, Graham DG, Montine TJ, and Ho YS. Enhanced N-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J Neuropathol Exp Neurol 59: 53-61, 2000.
224. Zhang J, Perry G, MSmith MA, Robertson D, Olson SJ, Graham DG, and Montine TJ. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154: 1423-1429, 1999.
225. Zhou W and Freed CR. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T {alpha}-synuclein toxicity. J Biol Chem 280: 43150-43158, 2005.
226. Zipper LM and Mulcahy RT. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem 277: 36544-36552, 2002.